Company intelligence / Profile preview

OroScience

Palo Alto, California, United Statesrdhmag.com ↗

Ownership: Private
Development stage: Other

Overview

Periogenix has demonstrated safety and efficacy in clinical and animal studies for promoting post-surgical periodontal wound healing. Clinical experience suggests advanced states of healing with its use. Microcyn-based products are positioned to treat gingivitis and mucositis with biocompatible antimicrobial action.

Therapeutic areas: GastroenterologyInfectious DiseasesOther
Modalities: DeviceBiologic
Industry: Biotech

Partnerships

ACE Surgical Supply (distribution partner for Periogenix in US/Canada dental markets)Oculus Innovative Sciences/Oculus Innovative Sciences, Inc. ("Microcyn" technology licensing/distribution agreement)

Beyond the preview

Go deeper on OroScience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OroScience.

Explore the full profile